What You Should Know:
- Arecor Therapeutics, a biopharmaceutical company specializing in drug development and delivery, has announced two major strategic achievements: a co-development agreement with Sequel Med Tech and a royalty financing agreement with Ligand Pharmaceuticals Incorporated.
- The dual strategy is intended to accelerate the clinical development of its lead product, AT278, and extend the company's cash runway without diluting shareholders.
Co-Development:
Read More
insulin
Abbott & Tandem Integrate to Bring Automated Insulin Delivery to US
What You Should Know:
- Tandem Diabetes Care and Abbott have joined forces to bring the first automated insulin delivery (AID) system in the US compatible with Abbott's latest FreeStyle Libre 2 Plus sensor.
- The integration brings the benefits of advanced closed-loop technology to millions of Americans living with diabetes, helping them achieve better blood sugar control and manage their condition with greater ease.
Seamless Integration for Precise Control:
The t:slim X2 insulin
Read More
GoodRx Now Offers Access to $35 Insulin to All Americans
What You Should Know:
- GoodRx today announced it is working with Sanofi, a global leader in diabetes care, to offer a new way for people living with diabetes to access Lantus® (insulin glargine injection) 100 Units/mL in the U.S. for only $35.
- This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap out-of-pocket costs at $35 for all patients with commercial insurance, which goes into effect January 1, 2024. It leverages GoodRx’s reach
Read More
Expectations For The Connected Care Business In The Years Ahead
Though we seldom see their use in our modern world and, even then, only in fiction, there was a time when it was common for people to actually use things like crystal balls and divining rods to try to uncover unknown yet valuable information. As unbelievable as it may seem, soothsayers peered into crystal balls aiming to help seekers look into the future for guidance, while prospectors would rely earnestly on divining rods as they attempted to locate underground riches of water or oil.
While
Read More
How AI Can Deliver Benefits in Healthcare Manufacturing and Patient Device Usage
According to Grand View Research, the global artificial intelligence (AI) in the healthcare market size was valued at USD 15.4 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 37.5% from 2023 to 2030, to reach an estimated USD 208.2 billion. That’s an impressive growth rate, indicating the expected value delivery to a mostly early-phase adoption of AI in the healthcare marketplace. With such aggressive predicted growth, many health industry professionals
Read More
Glytec Unveils Real-Time Analytics to Help Hospitals Prepare for New CMS Measures
What You Should Know:
Glytec, the only provider of cloud-based insulin management software across the continuum of care, today announced the next evolution of GlucoMetricsⓇ to provide new analytics, dashboards and data visualizations that give hospitals and health systems new insight into glycemic outcomes. The enhanced visibility this provides is essential as hospitals prepare for new measures from the Centers for Medicare and Medicaid Services (CMS) on severe hypoglycemia and hyperglycemia
Read More
Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients
What You Should Know:
- Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance. The price cut goes into effect January 1, 2024.
- The price cut milestone comes in addition to decisions taken in June 2022 to lower diabetes medicines costs: the launch of an unbranded Lantus biologic at -60% versus Lantus list price, and a cap on out-of-pocket costs on insulin to $35 for all people
Read More
Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B
What You Should Know:
- Sanofi has agreed to acquire Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), for $25.00 per share in cash, representing an equity value of approximately $2.9B.
- The acquisition is a strategic fit for Sanofi at the intersection of the company’s growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet
Read More
Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month
What You Should Know:
- Eli Lilly and Company today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month at participating retail pharmacies.
- The historic price cut makes it easier to access Lily insulin for Americans who may have difficulty navigating a complex healthcare system that may keep them from getting affordable
Read More
Dexcom Ventures Invests in MedCrypt’s Medical Device Cybersecurity Platform
What You Should Know:
- MedCrypt, the proactive cybersecurity solution provider for medical devices and manufacturers, will announce the close of a Series B extension round led by Dexcom Ventures, bringing the company's total to date to $36.4M.
- With support from three major investors, Johnson & Johnson Innovations, Intuitive Ventures, and Dexcom Ventures, MedCrypt continues to lead the way in developing cybersecurity technologies and infrastructure for life-saving medical
Read More
